Fig 1.From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china Schematic of the Decision Tree and Markov Model. ACTH Doxorubicin/Cyclophosphamide/Paclitaxel/Trastuzumab, TCH Docetaxel/Carboplatin/Trastuzumab)Back to article page